Department of Pharmacy, College of Pharmacy, Pusan National Universitygrid.262229.f, Busan, South Korea.
Microbiol Spectr. 2021 Oct 31;9(2):e0078221. doi: 10.1128/Spectrum.00782-21. Epub 2021 Oct 27.
Pseudomonas aeruginosa, an opportunistic human pathogen, expresses protease IV (PIV) for infection. Since the PIV activity can be inhibited by its propeptide, we tried to alleviate the severity of P. aeruginosa infection using the purified PIV propeptide (PIV). The PIV treatment of P. aeruginosa could significantly inhibit the PIV activity and reduce the virulence of P. aeruginosa in multiple invertebrate infection models, such as nematodes, brine shrimp, and mealworms. The effectiveness of PIV was further confirmed using mouse skin infection and acute/chronic lung infection models. The amount of PIV that inhibited the PIV activity of P. aeruginosa by 65% could alleviate the severity of infection significantly in all of the skin and acute/chronic lung infections. In addition, the PIV treatment of P. aeruginosa facilitated the healing of the skin wound infections and repressed the growth of P. aeruginosa in the infected lung. The PIV itself did not cause the induction of inflammatory cytokines or have any harmful effects on host tissues and did not affect bacterial growth. Taken together, P. aeruginosa infections can be alleviated by PIV treatment. Pseudomonas aeruginosa is a highly antibiotic-resistant pathogen and is extremely difficult to treat. Instead of using conventional antibiotics, we attempted to alleviate P. aeruginosa infection using factors that P. aeruginosa itself produces naturally. Extracellular proteases are powerful virulence factors and important targets to control the P. aeruginosa infections. Propeptides are originally expressed as part of extracellular proteases, inhibiting their activity until they go out of the cell, preventing them from becoming toxic to the cells themselves. We confirmed, from multiple animal experiments, that treating P. aeruginosa with the purified propeptide can alleviate its infectivity. Propeptides specifically inhibit only their cognate protease without inhibiting other essential proteases of the host. The development of resistance can be avoided because the propeptide-mediated inhibition is an inherent mechanism of P. aeruginosa; hence, it will be difficult for P. aeruginosa to alter this mechanism. Since propeptides do not affect bacterial growth, there is no selective pressure to develop resistant cells.
铜绿假单胞菌是一种机会性人类病原体,它会表达蛋白酶 IV(PIV)以进行感染。由于 PIV 的活性可以被其前肽所抑制,我们尝试使用纯化的 PIV 前肽(PIV)来减轻铜绿假单胞菌感染的严重程度。PIV 处理铜绿假单胞菌可以显著抑制 PIV 活性,并降低铜绿假单胞菌在多种无脊椎动物感染模型中的毒力,如线虫、卤虫和粉虫。我们使用小鼠皮肤感染和急性/慢性肺感染模型进一步证实了 PIV 的有效性。抑制 65%的 PIV 活性的 PIV 量可以显著减轻所有皮肤和急性/慢性肺感染的严重程度。此外,PIV 处理铜绿假单胞菌促进了皮肤伤口感染的愈合,并抑制了感染肺中的铜绿假单胞菌生长。PIV 本身不会引起炎症细胞因子的诱导,也不会对宿主组织造成任何有害影响,也不会影响细菌的生长。总之,PIV 处理可以减轻铜绿假单胞菌感染。铜绿假单胞菌是一种高度抗药性的病原体,极难治疗。我们没有使用传统抗生素,而是尝试使用铜绿假单胞菌自身天然产生的因子来减轻铜绿假单胞菌感染。细胞外蛋白酶是强大的毒力因子,是控制铜绿假单胞菌感染的重要靶点。前肽最初是作为细胞外蛋白酶的一部分表达的,抑制其活性,直到它们离开细胞,防止它们对自身细胞产生毒性。我们通过多项动物实验证实,用纯化的前肽处理铜绿假单胞菌可以减轻其传染性。前肽特异性抑制其同源蛋白酶,而不抑制宿主的其他必需蛋白酶。由于前肽介导的抑制是铜绿假单胞菌固有的机制,因此可以避免产生耐药性。由于前肽不影响细菌的生长,因此没有产生耐药细胞的选择性压力。